Cabozantinib
Cabometyx · VEGFR/MET TKI
Hypertension and proteinuria; nephrotic case reports.
Fotivda · Tivo
VEGFR TKI · approved 2021 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A highly selective VEGFR inhibitor for refractory RCC, with hypertension as its hallmark on-target toxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
In the phase III TIVO-3 trial, hypertension was the most common grade 3-4 treatment-related adverse event, occurring in about 20% of tivozanib-treated patients; proteinuria occurs as a VEGFR class effect but is comparatively less prominent.Source: Rini et al., Lancet Oncol 2020 (TIVO-3, grade 3-4 hypertension)
Within the first weeks of therapy.
Distilled from: “Within the first weeks of therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Grade 3/4 hypertension in 20% (35/173) — the most common grade 3/4 treatment-related adverse event in the phase III TIVO-3 trial (third/fourth-line metastatic RCC).
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Tap a signature to trace where it strikes the nephron.
Representative grade ≥3 incidence
Hypertension strikes: Glomerulus, Vasculature / Endothelium.
Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
§ Receptor target map
VEGFR2 is the target with documented renal consequences across every VEGFR TKI; multi-kinase breadth beyond it (PDGFR-β, FGFR, and off-target receptor kinases) adds further renal and hypertensive liability. Select a lit receptor for its renal consequence.
VEGFR2 · renal target
Glomerular endothelial VEGFR2: loss of podocyte-derived paracrine VEGF signaling → fenestrae loss, nephrin downregulation, nitric-oxide depletion → hypertension, proteinuria, and thrombotic microangiopathy.
Potent, highly selective inhibitor of VEGFR1-3 with a long half-life, suppressing tumor angiogenesis with relatively few off-target kinase effects (which contributes to a comparatively clean non-renal toxicity profile). Approved for relapsed or refractory advanced renal cell carcinoma after two or more prior systemic therapies.
Class-level context for the major non-renal toxicities of the VEGFR TKI class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dosage modification is recommended for patients with mild to severe renal impairment (creatinine clearance [CLcr] 15-89 mL/min, estimated by Cockcroft-Gault). The recommended dosage for patients with end-stage renal disease has not been established [see CLINICAL PHARMACOLOGY (12.3) ] .
Kidney rows of the label's dosage tables
From the FOTIVDA label (Sep 2026) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. A cell marked fn carries one of those footnotes on the label. Educational only, not medical advice.
| Adverse Reaction | Severityfn | Dosage Modifications for FOTIVDA |
|---|---|---|
| Proteinuria [see Warnings and Precautions (5.6)] | 2 grams or greater proteinuria in 24 hours | Withhold until less than or equal to 2 grams of proteinuria per 24 hours. Resume at a reduced dose. Permanently discontinue for nephrotic syndrome. |
Everything below is FAERS — adverse events someone chose to report, about 1,588 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
157 of 1,588 reports
Reported with hospitalization
347 of 1,588 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1 of the 1,588 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Tivozanib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Cabometyx · VEGFR/MET TKI
Hypertension and proteinuria; nephrotic case reports.
Lenvima · VEGFR TKI
Highest-ranked TKI for hypertension; proteinuria.
Stivarga · VEGFR TKI
Hypertension and proteinuria.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.